The biology of castration-resistant prostate cancer.
作者信息
Lian Fei, Sharma Nitya V, Moran Josue D, Moreno Carlos S
出版信息
Curr Probl Cancer. 2015 Jan-Feb;39(1):17-28. doi: 10.1016/j.currproblcancer.2014.11.004. Epub 2014 Nov 25.
Abstract
摘要
相似文献
1
The biology of castration-resistant prostate cancer.去势抵抗性前列腺癌的生物学
Curr Probl Cancer. 2015 Jan-Feb;39(1):17-28. doi: 10.1016/j.currproblcancer.2014.11.004. Epub 2014 Nov 25.
2
Targeting the androgen receptor in metastatic castration-resistant prostate cancer.靶向转移性去势抵抗性前列腺癌中的雄激素受体
Future Oncol. 2014 Feb;10(3):329-32. doi: 10.2217/fon.13.255.
3
Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.靶向去势抵抗性前列腺癌中的雄激素受体异常
Clin Cancer Res. 2016 Sep 1;22(17):4280-2. doi: 10.1158/1078-0432.CCR-16-1137. Epub 2016 Jun 21.
4
Galeterone activity in castration-resistant prostate cancer.加列酮在去势抵抗性前列腺癌中的活性
Lancet Oncol. 2015 Jan;16(1):e10. doi: 10.1016/S1470-2045(14)71165-9. Epub 2014 Nov 28.
5
[New generation of androgen receptor antagonist in castration resistant prostate cancer].[去势抵抗性前列腺癌中的新一代雄激素受体拮抗剂]
Nihon Rinsho. 2014 Dec;72(12):2164-9.
6
Androgen receptors in early and castration resistant prostate cancer: friend or foe?早期及去势抵抗性前列腺癌中的雄激素受体：是友还是敌？
Hormones (Athens). 2013 Apr-Jun;12(2):224-35. doi: 10.14310/horm.2002.1406.
7
Update on systemic therapy for advance prostate cancer.晚期前列腺癌全身治疗的最新进展
Curr Probl Cancer. 2015 Jan-Feb;39(1):52-62. doi: 10.1016/j.currproblcancer.2014.11.009. Epub 2014 Nov 25.
8
Leading causes of castration-resistant prostate cancer.去势抵抗性前列腺癌的主要病因。
Expert Rev Anticancer Ther. 2015 Apr;15(4):425-32. doi: 10.1586/14737140.2015.1007957. Epub 2015 Feb 3.
9
Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials.新型雄激素受体通路靶向药物在去势抵抗性前列腺癌治疗中的作用：基于随机试验的文献荟萃分析。
Eur J Cancer. 2016 Jul;61:111-21. doi: 10.1016/j.ejca.2016.04.002. Epub 2016 May 7.
10
Molecular alterations and emerging targets in castration resistant prostate cancer.雄激素剥夺治疗抵抗性前列腺癌的分子改变与新靶点
Eur J Cancer. 2014 Mar;50(4):753-64. doi: 10.1016/j.ejca.2013.12.004. Epub 2014 Jan 10.
引用本文的文献
1
Azolato-Bridged Dinuclear Platinum(II) Complexes Exhibit Androgen Receptor-Mediated Anti-Prostate Cancer Activity.唑桥联双核铂(II)配合物表现出雄激素受体介导的抗前列腺癌活性。
Inorg Chem. 2024 Nov 4;63(44):20951-20963. doi: 10.1021/acs.inorgchem.4c01093. Epub 2024 Sep 11.
2
Characterization and Survival Benefit of Drug Approvals for Metastatic Prostate Cancer, 2004 to 2022.2004年至2022年转移性前列腺癌药物获批情况及其生存获益
Clin Med Insights Oncol. 2024 Feb 6;18:11795549241227413. doi: 10.1177/11795549241227413. eCollection 2024.
3
Two calix[4]pyrroles as potential therapeutics for castration-resistant prostate cancer.两种杯[4]吡咯作为治疗去势抵抗性前列腺癌的潜在药物。
Invest New Drugs. 2022 Dec;40(6):1185-1193. doi: 10.1007/s10637-022-01294-8. Epub 2022 Aug 17.
4
Oxidative stress and redox signaling in CRPC progression: therapeutic potential of clinically-tested Nrf2-activators.去势抵抗性前列腺癌进展中的氧化应激与氧化还原信号传导：经临床测试的Nrf2激活剂的治疗潜力
Cancer Drug Resist. 2021 Mar 19;4(1):96-124. doi: 10.20517/cdr.2020.71. eCollection 2021.
5
Natural Product-Based Studies for the Management of Castration-Resistant Prostate Cancer: Computational to Clinical Studies.基于天然产物的去势抵抗性前列腺癌治疗研究：从计算研究到临床研究
Front Pharmacol. 2021 Oct 19;12:732266. doi: 10.3389/fphar.2021.732266. eCollection 2021.
6
Signaling Pathways That Control Apoptosis in Prostate Cancer.控制前列腺癌细胞凋亡的信号通路。
Cancers (Basel). 2021 Feb 24;13(5):937. doi: 10.3390/cancers13050937.
7
Efficacy of docetaxel combined carboplatin for the treatment of patients with castration-resistant prostate cancer: A protocol of systematic review and meta-analysis.多西他赛联合卡铂治疗去势抵抗性前列腺癌患者的疗效：一项系统评价和荟萃分析方案
Medicine (Baltimore). 2020 May 22;99(21):e20297. doi: 10.1097/MD.0000000000020297.
8
The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression.JNK抑制剂AS602801与恩杂鲁胺协同作用，在体外和体内杀死前列腺癌细胞并抑制雄激素受体表达。
Transl Oncol. 2020 Apr;13(4):100751. doi: 10.1016/j.tranon.2020.100751. Epub 2020 Mar 18.
9
Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies.镥-177 前列腺特异性膜抗原（PSMA）放射性药物治疗：实用的细微差别和复杂性。
Prostate Cancer Prostatic Dis. 2020 Mar;23(1):38-52. doi: 10.1038/s41391-019-0174-x. Epub 2019 Oct 8.
10
Novel Method for Structure-Activity Relationship of Aptamer Sequences for Human Prostate Cancer.用于人前列腺癌适配体序列构效关系的新方法
ACS Omega. 2018 Aug 28;3(8):10002-10007. doi: 10.1021/acsomega.8b01464. eCollection 2018 Aug 31.
本文引用的文献
1
Demethylation of the miR-146a promoter by 5-Aza-2'-deoxycytidine correlates with delayed progression of castration-resistant prostate cancer.5-氮杂-2'-脱氧胞苷使miR-146a启动子去甲基化与去势抵抗性前列腺癌的进展延迟相关。
BMC Cancer. 2014 May 2;14:308. doi: 10.1186/1471-2407-14-308.
2
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.PTEN-TP53 缺陷型前列腺癌对复合 PARP-PI3K 抑制的易感性。
Cancer Discov. 2014 Aug;4(8):896-904. doi: 10.1158/2159-8290.CD-13-0230. Epub 2014 May 27.
3
PTEN-deficient tumors depend on AKT2 for maintenance and survival.PTEN 缺陷型肿瘤依赖 AKT2 来维持和生存。
Cancer Discov. 2014 Aug;4(8):942-55. doi: 10.1158/2159-8290.CD-13-0873. Epub 2014 May 16.
4
Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy.跨物种调控网络分析鉴定出 FOXM1 和 CENPF 之间的协同相互作用，该作用驱动前列腺癌恶性进展。
Cancer Cell. 2014 May 12;25(5):638-651. doi: 10.1016/j.ccr.2014.03.017.
5
Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.在局部晚期和转移性前列腺癌患者中，使用曲普瑞林6个月剂型开始雄激素剥夺治疗时，评估尿前列腺癌抗原-3（PCA3）和TMPRSS2-ERG评分的变化。
BJU Int. 2014 Oct;114(4):608-16. doi: 10.1111/bju.12542. Epub 2014 Apr 4.
6
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.在去势抵抗性前列腺癌中靶向治疗 BET 溴结构域蛋白。
Nature. 2014 Jun 12;510(7504):278-82. doi: 10.1038/nature13229. Epub 2014 Apr 23.
7
Notch signaling in prostate cancer: a moving target. Notch 信号通路在前列腺癌中的作用：一个不断变化的靶点。
Prostate. 2014 Jun;74(9):933-45. doi: 10.1002/pros.22811. Epub 2014 Apr 16.
8
The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer.长链非编码RNA PCGEM1和PRNCR1与去势抵抗性前列腺癌无关。
Oncotarget. 2014 Mar 30;5(6):1434-8. doi: 10.18632/oncotarget.1846.
9
Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence.福尔马林固定前列腺癌标本的全转录组分析确定疾病复发的生物标志物。
Cancer Res. 2014 Jun 15;74(12):3228-37. doi: 10.1158/0008-5472.CAN-13-2699. Epub 2014 Apr 8.
10
Enzalutamide shows strong activity in prostate cancer.恩杂鲁胺在前列腺癌中显示出强大的活性。
Cancer Discov. 2014 Apr;4(4):OF2. doi: 10.1158/2159-8290.CD-NB2014-028. Epub 2014 Feb 20.
Zotero 插件